Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

PARIS and TARRYTOWN, New York, July 20, 2012 /PRNewswire/ --

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.  SAR236553/REGN727 is a potential first-in-class, subcutaneously administered, fully-human antibody that lowers low-density lipoprotein (LDL) cholesterol by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), an enzyme which binds LDL receptors, leading to their accelerated degradation and increased LDL-cholesterol (LDL-C) levels.

"We are delighted to lead the field of PCSK9 late stage development with the broad global 22,000 patient ODYSSEY clinical trial program, and would like to thank in advance the patients and physicians who will contribute to the first Phase 3 program evaluating a PCSK9-targeted therapy," said Jay Edelberg M.D., Ph.D., Head of the PCSK9 Development and Launch Unit, Sanofi.  "This comprehensive Phase 3 program will test the safety and efficacy of SAR236553/REGN727 administered as one single injection every two weeks in multiple treatment strategies and patient types, such as those who are at elevated cardiovascular risk, are unable to tolerate statin therapy, or have familial hypercholesterolemia."

"Lowering LDL-C remains the primary objective for the management of hypercholesterolemia and has been supported by numerous morbidity and mortality trials.  Despite the existence of very effective LDL-C lowering therapies, many patients, such as those with heterozygous familial hypercholesterolemia or those with elevated cardiovascular risk, are unable to achieve their LDL-C goals," said Professor Henry N. Ginsberg, M.D., Columbia University Medical Center,
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ... therapeutics that address unmet medical needs in women,s ... will present at the Cantor Fitzgerald Inaugural ... 2015Time: , 4:45 PM EDTLocation: , Le Parker ... , www.juniperpharma.com, under  ,Investor, or  click ...
(Date:6/30/2015)... WA (PRWEB) , ... June 30, 2015 , ... ... a hydrophilic filter that does not sacrifice selectivity to achieve faster flow rates ... combines extremely fine pores with significant open space to allow easy liquid flow ...
(Date:6/30/2015)... ... , ... Matrix Marketing Group, LLC , a leading provider of performance-based ... up its account management department as vice president of client services. Amanda Gregory ... management and delivery expertise to the growing Matrix Marketing Group team in Denver, Colorado. ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2
... Copper,s days are numbered, and a new study ... the ubiquitous metal in smart phones, tablet computers, and ... who are seeking smaller, faster devices. As ... size, so do the copper pathways that transport electricity ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and ... Total revenue for the three months ended September ... period in the prior year. The increase was attributable to ... expenses were $325,000 for the three months ended September 30, ...
... Nov. 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... prevent and fight Human Immunodeficiency Virus (HIV) infections, today ... September 30, 2011. GeoVax reported a net ... months ended September 30, 2011, compared to $644,666 ($0.04 ...
Cached Biology Technology:Researching graphene nanoelectronics for a post-silicon world 2Researching graphene nanoelectronics for a post-silicon world 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/15/2015)... DALLAS , June 16, 2015 ... Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), ... Worldwide Forecast to 2020" published by MarketsandMarkets, The Natural ... Billion at a CAGR of 18.4% for the forecast ... Tables and   46 F igures spread   ...
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... food suppliers, policy-makers, business leaders and environmentalists are joining ... gas by taking part in an influential new forum ... Launched on February 22, the Nitrous Oxide Focus Group ... Farmers Union, Marks & Spencer, British Sugar, Defra, the ...
... trouble, primarily because the powerful muscles that propel ,their ... tasty. Prized by sushi lovers for their savory ... command-one 607-pound fish fetched over $90 per pound at ... have seen their population plummet in the past 50 ...
... could have prevented the collapse of the cod populations ... for tuna, says University of British Columbia fisheries economist ... generations of people are alive and negotiating with us ... his findings with UBC Fisheries Prof. Daniel Pauly at ...
Cached Biology News:Nitrous oxide: definitely no laughing matter 2To save or savor? It's decision time for Atlantic bluefin tuna 2To save or savor? It's decision time for Atlantic bluefin tuna 3To save or savor? It's decision time for Atlantic bluefin tuna 4To save or savor? It's decision time for Atlantic bluefin tuna 5To save or savor? It's decision time for Atlantic bluefin tuna 6To save or savor? It's decision time for Atlantic bluefin tuna 7UBC scientist invokes future generations to save tuna populations from collapse 2
St. Louis encephalitis Immunogen: St. Louis encephalitis. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Anti-Gemin2...
5-bromo-2'-deoxyuridine (BrdU) Cell Biology Cell Proliferation Bromodeoxyuridine (BrdU) and Related Products...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Biology Products: